Coenzyme Q, peroxidation and cytochrome oxidase features after Parkinson's-like disease by MPTP toxicity in intra-synaptic and non-synaptic mitochondria from Macaca Fascicularis cerebral cortex and hippocampus: Action of dihydroergocriptine

Neurochemical Research

Volumn 21, Issue 12, 1996, Pages 1505-1514

  Battino, M ^a   Littarru, G P ^a   Gorini, A ^b   Villa, R F ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Coenzyme Q; Cytochrome oxidase; Dihydroergocriptine; Hydroperoxides; Membrane fluidity; Parkinson's like syndrome

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYTOCHROME A; CYTOCHROME C OXIDASE; DIHYDROERGOCRYPTINE; DOPAMINE; FREE RADICAL; HYDROPEROXIDE; UBIDECARENONE; UBIQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN MITOCHONDRION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; HIPPOCAMPUS; INTRAVENOUS DRUG ADMINISTRATION; LIPID PEROXIDATION; MACACA; MALE; MEMBRANE FLUIDITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSONISM; PERIKARYON; PRIORITY JOURNAL; RESPIRATORY CHAIN;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; CEREBRAL CORTEX; DIHYDROERGOTOXINE; ELECTRON TRANSPORT COMPLEX IV; ENERGY METABOLISM; HIPPOCAMPUS; MACACA FASCICULARIS; MALE; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY; PEROXIDES; UBIQUINONE;

ANIMALIA; MACACA; MACACA FASCICULARIS;

EID: 0030477692     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02533098     Document Type: Article

References (60)

1. Mizuno, Y., Ikebe, S., Hattori, N., Kondo, T., Tanaka, M., and Ozawa, T. 1993. Mitochondrial energy crisis in Parkinson's disease. Adv. Neurol. 60:282-287.
2. Schapira, A. H. V. 1993. Mitochondrial complex I deficiency in Parkinson's disease. Adv. Neurol. 60:288-291.
3. Reichmann, H., Lestienne, P., Jellinger, K., and Riederer, P. 1993. Parkinson's disease and the electron transport chain in postmortem brain. Adv. Neurol. 60:297-299.
4. Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., and Marsden, C. D. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:823:827.
5. Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
6. Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., and Kopin, I. J. 1983. A primate model Parkinson's disease: selective destruction of substantia nigra, pars compacta dopaminergic neurons by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80:4546-4550.
7. Chiba, K., Trevor, A., and Castagnoli, N. 1984. Metabolism of the neurotoxic tertiary amine, MPTP by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:574-578.
8. Ramsay, R. R., Salach, J. I., Dadgar, J., and Singer, T. P. 1986. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem. Biophys. Res. Commun. 135:269-275.
9. Ramsay, R. R., Dadqar, J., Trevor, A., and Singer, T. P. 1986. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci. 39:581-588.
10. Vyas, I., Heikkila, R. E., and Nicklas, W. J. 1986. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J. Neurochem. 46:1501-1507.
11. Nicklas, W. J., Vyas, I., and Heikkila, R. E. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine a metabolite of the neurotoxin, 1-methyl-4-phenyl,2,5,6-tetrahydropyridine. Life Sci. 36:2503-2508.
12. + and mitochondrial function. Life Sci. 40: 721-729.
13. Villa, R. F., Arnaboldi, R., Ghigini, B., and Gorini, A. 1992. Mitochondrial factors involved in Parkinson's disease by MPTP toxicity in Macaca Fascicularis and drug effect. Neurochem. Res. 17:1147-1154.
14. Villa, R. F., Arnaboldi, R., Ghigini, B., and Gorini, A. 1994. Parkinson-like disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity in Macaca Fascicularis: synaptosomal metabolism and action of dihydroergocriptine. Neurochem. Res. 19:229-236.
15. Battino, M., Fern, E., Gorini, A., Villa R. F., Huertas, J. F. R., Fiorella, P. L., Genova, M. L., Lenaz, G., and Marchetti, M. 1990. Natural distribution and occurrence of Coenzyme Q homologues. Membr. Biochem. 9:179-190.
16. Hattori, N., Ikebe, S., Tanaka, M., Ozawa, T., and Mizuno, Y. 1993. Immunoistochemical studies on complexes I, II, III and IV of mitochondria in Parkinson's disease. Adv. Neurol. 60:292-296.
17. Nagatsu, T. 1993. Biochemical aspects of Parkinson's disease. Adv. Neurol. 60:165-174.
18. Mizuno, Y., Sone, N., and Saitoh, T. 1987. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J. Neurochem. 48:1787-1793.
19. 10 content induced by dietary fat and endogenous lipid peroxidation. FEBS Lett. 287:89-92.
20. Quiles, J. L., Huertas, J. R., Manas, M., Battino, M., Cassinello, M., Littarru, G. P., Lenaz, G., and Mataix, F. J. 1994. Peroxidative extent and Coenzyme Q levels in the rat: influence of physical training and dietary fats. Molec. Aspects Med. 155:89-95.
21. Huertas, J. R., Battino, M., Mataix, F. J., and Lenaz, G. 1991. Cytochrome oxidase induction after oxidative stress induced by adriamycin in liver if rats fed with dietary olive oil. Biochem. Biophys. Res. Commun. 181:375-382.
22. Szabo, J., and Cowan, W. M. 1984. A stereotaxic atlas of the brain of the Cynomolgus monkey (Macaca Fascicularis). J. Comp. Neurol. 222:265-300.
23. Lai, J. C. K., Walsh, J. M., Dennis, S. C., and Clark, J. B. 1977. Synaptic and non-synaptic mitochondria from rat brain: isolation and characterization. J. Neurochem. 28:625-631.
24. Villa, R. F., Gorini, A., LoFaro, A., and Dell'Orbo, C. 1989. A critique on the preparation and enzymatic characterization of synaptic and nonsynaptic mitochondria from hippocampus. Cell. Mol. Neurobiol. 9:247-262.
25. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
26. Smith, L., Davies, H. C., and Nava, M. 1974. Oxidation and reduction of soluble cytochrome c by membrane-bound oxidase and reductase systems. J. Biol. Chem. 249:2904-2910.
27. Vanneste, V. H. 1966. Molecular proportion of the fixed cytochrome components of the respiratory chain of Keilin-Hartree particles and beef heart mitochondria. Biochim. Biophys. Acta 113: 175-178.
28. Battino, M., Bertoli, E., Formiggini, G., Sassi, S., Gorini A., Villa, R. F., and Lenaz, G. 1991. Structural and functional aspects of the respiratory chain of synaptic and nonsynaptic mitochondria derived from selected brain regions. J. Bioenerg. Biomembr. 23: 345-363.
29. Kroger, A. 1978. Determination of contents and redox state of ubiquinone and menaquinone. Methods Enzymol. 53:579-591.
30. Jiang, Z. Y., Hunt, J. V., and Wolff, S. P. 1992. Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. Anal. Biochem. 202: 384-389.
31. Van Blitterswijk, W. J., Van Hoeven, R. P., and Van der Meer, B. W. 1981. Lipid structural order parameters (reciprocal of fluidity) in biomembranes derived from steady-state fluorescence polarization measurements. Biochim. Biophys. Acta 644:323-332.
32. Brasitus, T. A., Yeh, K.-Y., Holt, P. R., and Schacter, D. 1984. Lipid fluidity and composition of intestinal microvillus membranes isolated from rats of different ages. Biochim. Biophys. Acta 778:341-348.
33. Shinitzky, M., and Inbar, M. 1976. Microviscosity parameters and protein mobility in biological membranes. Biochim. Biophys. Acta 433:133-139.
34. Shinitzky, M., and Barenholz, Y. 1978. Fluidity parameters of lipid regions determined by fluorescence polarization. Biochim. Biophys. Acta 515:367-394.
35. Markstein, R. 1983. Dopamine receptor profile of co-dergocrine (Hydergine) and its components. Eur. J. Pharmacol. 86:145-155.
36. Calne, D. B., Kartzinel, R., and Shoulson, I. 1976. An ergot derivative in the treatment of Parkinson's disease. Post-grad. Med. J. 52:81-83.
37. Agnoli, A., Martucci, N., and Manna, V. 1987. Ergot dopaminergic agonists and Parkinson dementia. Vol. 1, pages 89-96, in Bes, A., Cahan, R., and Hoyer, S. (eds.), Senile Dementia: Early Detection: Current Problems in Senile Dementia, International Symposium on Senile Dementia: Early Detection, Paris.
38. Benzi, G., Arrigoni, E., Pastoris, O., Dossena, M., Gorini, A., and Villa, R. F. 1983. Effects of ergot derivatives on the metabolic changes induced by acute hypoxia on the synaptosomes from dog brain. Vol. 23, pages 263-282, in Agnoli, A., Crepaldi, G., Spano, P. F., and Trabucchi, M. (eds.), Aging Brain and Ergot Alkaloids, Raven Press, New York.
39. Benzi, G., Villa, R. F., Dossena, M., Vercesi, L., Gorini, A., and Pastoris, O. 1984. Role of drugs in recovery of metabolic function of rat brain following severe hypoglycemia. Neurochem. Res. 9: 979-992.
40. Benzi, G., Pastoris, O., and Villa, R. F. 1988. Changes induced by aging and drug treatment on cerebral enzymatic antioxidant system. Neurochem. Res. 13:467-478.
41. Dexter, D. T., Sian, J., Jenner, P., and Marsden, C. D. 1993. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv. Neurol. 60:273-281.
42. Lenaz, G., Barnabei, O., Rabbi, A., and Battino, M. (eds.) 1990. Highlights in Ubiquinone Research. Taylor & Francis, London.
43. Folkers, K., Littarru, G. P., and Yamagami, T. (eds.) 1991. Biomedical and Clinical Aspects of Coenzyme Q. Vol. VI, Elsevier, Amsterdam.
44. Folkers, K., Mortensen, S. A., Littarru, G. P., Yamagami, T., and Lenaz. (eds.) 1993. The Biomedical and Clinical Aspects of Coenzyme Q. Clin. Invest. 718:51-176.
45. Battino, M., Ferri, E., Girotti, S., and Lenaz, G. 1991. Free radicals scavenging activity of Coenzyme Q detected by a chemiluminescent assay. Anal. Chim. Acta 255:367-371.
46. Ferri, E., Feroci, G., Gattavecchia, E., and Battino, M. 1994. Interaction between reactive oxygen study. Molec. Aspects Med., 155:83-88.
47. Baker, J. M., and Weinstein, I. B. 1980. Mitochondrial DNA is a major cellular target for a dihydrodiol-epoxide derivative of benzo(a)pyrene. Science 209:297-299.
48. Linnane, A. W., Marzuki, S., and Ozawa, T. 1989. Mitochondrial DNA mutations as an important contributor to aging and degenerative diseases. Lancet i:642-645.
49. Cleeter, M. J. W., Cooper, J. M., and Schapira, A. H. V. 1992. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58:786-789.
50. Lenaz, G. 1987. Lipid fluidity and membrane protein dynamics. Biosci. Rep. 7:823-837.
51. 3H]dihydrorotenone. FEBS Lett. 219:108-113.
52. Ozawa, T., Tanaka, M., and Ikebe, S. 1990. Quantitative determinations of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. Biochem. Biophys. Res: Commun. 172:483-489.
53. Turrens, J. F., and Boveris A. 1980. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem. J. 191:421-427.
54. + induces NADH dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170:1049-1055.
55. Bindoff, L. A., Birch-Machin, M., and Cartlidge N. E. F. 1989. Mitochondrial function in Parkinson's disease. Lancet ii:49.
56. Shoffner, J. M., Watts, R. L., and Juncos, J. L. 1991. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann. Neurol. 30:332-339.
57. Fahn, S. 1991. An open trial of high-dosage antioxidants in early Parkinson's disease. Am. J. Clin. Nutr. 53:3803-3825.
58. Cadenas, E., and Packer, L. (eds.) 1995. Handbook of antioxidants: Chemical, Biochemical and Clinical Aspects, Marcel Dekker, New York.
59. 10 levels in Parkinson Syndrome 1994. Vol. 6, pages 159-166, in Folkers K., Littarru G. P. and Yamagami T. (eds.), Biomedical and Clinical Aspects of Coenzyme Q, Elsevier, Amsterdam.
60. Fariello, R. G., Ghirardi, O., Peschera, A., Ramacci, M. T., and Angelucci, L. 1987. Transient nigral ubiquinone depletion after single MPTP administration in mice. Neuropharmacol. 26:1799-1802.